Study results How much weight do people lose on Zepbound (SURMOUNT-1)? “Study 1 (NCT04184622) was a 72-week trial that enrolled 2,539 adult patients with obesity (BMI ≥30 kg/m2), or with overweight (BMI 27 to <30 kg/m2) and at least one weight-related comorbid condition, such as dyslipidemia, hypertension, obstructive sleep apnea, or CV disease; patients with type 2 diabetes mellitus were excluded. Patients were randomized in a 1:1:1:1 ratio to once weekly fixed dosage of ZEPBOUND 5 mg, ZEPBOUND 10 mg, ZEPBOUND 15 mg, or placebo, with an escalation period of up to 20 weeks followed by the maintenance period.” (opens the source at this quote in a new tab) Copy Flag
“Table 2: Changes in Body Weight at Week 72 in Studies 1 and 2 in Patients with Obesity or Overweight
Abbreviations: ANCOVA = analysis of covariance; CI = confidence interval; N = number of patients randomly assigned to study drug.
a The intention-to-treat population includes all randomly assigned patients. For Study 1 at Week 72, body weight was missing for 21.6%, 10.2%, 10.5%, and 9.4% of patients randomly assigned to placebo, ZEPBOUND 5 mg, 10 mg, and 15 mg, respectively. For Study 2 at Week 72, body weight was missing for 11.1%, 4.8%, and 8.4% of patients randomly assigned to placebo, ZEPBOUND 10 mg, and 15 mg, respectively. The missing values were imputed by a hybrid approach using retrieved dropouts from the same treatment group (if missing not due to COVID-19) or using all non-missing data assuming missing at random (for missing solely due to COVID-19).
b Least-squares mean from ANCOVA adjusted for baseline value and other stratification factors.
c Analyzed using logistic regression adjusted for baseline value.
d p-value<0.001 (unadjusted 2-sided) for superiority, controlled for type I error rate.
e Not controlled for type I error rate.
Study 1 Study 2
Intention-to-Treat (ITT) Populationa
Placebo
N = 643 ZEPBOUND
5 mg
N = 630 ZEPBOUND
10 mg
N = 636 ZEPBOUND
15 mg
N = 630
Placebo
N = 315 ZEPBOUND
10 mg
N = 312 ZEPBOUND
15 mg
N = 311
Body Weight
Baseline mean (kg) 104.8 102.9 105.8 105.6 101.7 100.9 99.6
% Change from baselineb -3.1 -15.0 -19.5 -20.9 -3.2 -12.8 -14.7
% Difference from placebob
(95% CI) -11.9
(-13.4, -10.4)d -16.4
(-17.9, -14.8)d -17.8
(-19.3, -16.3)d -9.6
(-11.1, -8.1)d -11.6
(-13.0, -10.1)d” (opens the source at this quote in a new tab) Copy Flag
Note: Table 2 columns are, for Study 1, placebo, ZEPBOUND 5 mg, 10 mg, and 15 mg, then, for Study 2, placebo, ZEPBOUND 10 mg, and 15 mg. Study 1 of the Prescribing Information has the same duration and enrollment (72 weeks, 2,539 patients) as SURMOUNT-1 on the Zepbound HCP site.
Zepbound: how many people lose 5%, 10%, 15%, or 20% of their weight? “% of Patients losing ≥5% body weight 34.5 85.1 88.9 90.9 32.5 79.2 82.8
% Difference from placebo
(95% CI) 50.3
(44.3, 56.2)c,d 54.6
(49.1, 60.0)c,d 56.4
(50.9, 62.0)c,d 46.8
(39.5, 54.1)c,d 50.4
(43.1, 57.8)c,d
% of Patients losing ≥10% body weight 18.8 68.5 78.1 83.5 9.5 60.5 64.8
% Difference from placebo
(95% CI) 49.3
(43.6, 54.9)c,e 59.5
(54.2, 64.9)c,d 64.8
(59.6, 70.1)c,d 51.0
(44.4, 57.7)c,d 55.3
(48.6, 62.0)c,d
% of Patients losing ≥15% body weight 8.8 48.0 66.6 70.6 2.7 39.7 48.0
% Difference from placebo
(95% CI) 38.7
(33.6, 43.7)c,e 58.1
(53.2, 63.0)c,d 62.0
(57.2, 66.8)c,d 37.0
(31.1, 42.9)c,d 45.4
(39.4, 51.4)c,d
% of Patients losing ≥20% body weight 3.1 30.0 50.1 56.7 1.0 21.5 30.8
% Difference from placebo
(95% CI) 26.6
(22.4, 30.7)c,e 47.3
(42.7, 51.9)c,d 53.8
(49.3, 58.3)c,d 20.5
(15.7, 25.4)c,d 29.7
(24.3, 35.0)c,d” (opens the source at this quote in a new tab) Copy Flag
Note: Table 2 columns are, for Study 1, placebo, ZEPBOUND 5 mg, 10 mg, and 15 mg, then, for Study 2, placebo, ZEPBOUND 10 mg, and 15 mg. Studies 1 and 2 have the same duration and enrollment as SURMOUNT-1 (2,539 patients) and SURMOUNT-2 (938 patients) on the Zepbound HCP site.
How many people on Zepbound lose 25% or more of their body weight? “Bar graph showing the percentage of adults who had ≥25% weight loss in the SURMOUNT-1 trial (Zepbound 5 mg, 10 mg, and 15 mg vs placebo at 72 weeks). There were 630, 636, 630, and 643 total adults for Zepbound 5 mg, 10 mg, 15 mg, and placebo, respectively. The mean baseline weights were 226.8 lb for Zepbound 5 mg, 233.3 lb for Zepbound 10 mg, 232.8 lb for Zepbound 15 mg, and 231.0 lb for placebo. The percentage of adults achieving ≥25% weight loss was 15.3% for Zepbound 5 mg, 32.3% for Zepbound 10 mg, and 36.2% for Zepbound 15 mg vs 1.5% for placebo.” (opens the source at this quote in a new tab) Copy Flag
On the page, select: Show description
Zepbound in type 2 diabetes: how much weight do people lose (SURMOUNT-2)? Applies to Weight reduction in adults with overweight or obesity and type 2 diabetes (SURMOUNT-2)
Note: In the Table 2 rows, the last three columns are Study 2: placebo, ZEPBOUND 10 mg, and 15 mg. Study 2 of the Prescribing Information has the same duration and enrollment (72 weeks, 938 patients) as SURMOUNT-2 on the Zepbound HCP site.
Does Zepbound add weight loss after an intensive lifestyle program (SURMOUNT-3)? “Table 4: Changes in Body Weight After 12-Week Intensive Lifestyle Intervention Lead-In Followed by Randomized Treatment and a Standard Lifestyle Intervention (Study 3) in Patients with Obesity or Overweight
Abbreviations: ANCOVA = analysis of covariance; CI = confidence interval; MTD = maximum tolerated dose; N = number of patients randomly assigned to study drug.
a The intent-to-treat population included only randomized patients with ≥5% weight loss at Week 0 after 12 weeks of intensive lifestyle intervention. During the 12-week lead-in period, 227 of 806 patients (28.2%) discontinued from the study. Of these 141 (17.5%) discontinued due to not achieving the randomization criteria of ≥5% weight reduction.
b The intent-to-treat population includes all randomly assigned patients. For Study 3 at Week 72, body weight was missing for 23.6% and 8.7% of patients randomly assigned to placebo and ZEPBOUND MTD (10 or 15 mg). The missing values were imputed by a hybrid approach using retrieved dropouts from the same treatment group (if missing not due to COVID-19) or using all non-missing data assuming missing at random (for missing solely due to COVID-19).
c Least-squares mean from ANCOVA adjusted for baseline value and other stratification factors.
d Analyzed using logistic regression adjusted for baseline value.
e p-value<0.001 (unadjusted 2-sided) for superiority, controlled for type I error rate.
Study 3
N = 579a
Body Weight
Mean (kg) at Week -12 109.5
Intention-to-Treat (ITT) Populationa,b
Placebo
N = 292 ZEPBOUND
MTD (10 mg or 15 mg)
N = 287
Body Weight
Mean (kg) at Week 0 101.3 102.5
% Change from randomization at Week 72c 2.5 -18.4
% Difference from placebo, at Week 72c
(95% CI) -20.8
(-23.2, -18.5)e
% of Patients losing ≥5% body weight 16.5 87.5
% Difference from placebo
(95% CI) 71.1
(63.6, 78.5)d,e
% of Patients losing ≥10% body weight 8.9 76.7
% Difference from placebo
(95% CI) 67.9
(60.7, 75.1)d,e
% of Patients losing ≥15% body weight 4.2 65.4
% Difference from placebo
(95% CI) 61.3
(54.5, 68.1)d,e
% of Patients losing ≥20% body weight 2.2 44.7
% Difference from placebo
(95% CI) 42.6
(36.0, 49.1)d,e” (opens the source at this quote in a new tab) Copy Flag
Note: Table 4 columns are placebo and ZEPBOUND MTD (10 mg or 15 mg), in that order. Study 3 of the Prescribing Information has the same design and enrollment (806 enrolled, 579 randomized) as SURMOUNT-3 on the Zepbound HCP site.
Do people regain weight after stopping Zepbound (SURMOUNT-4)? Note: Table 6 columns are placebo and ZEPBOUND MTD (10 mg or 15 mg), in that order. The week 88 values from week 0 are from the clinical data page of the Zepbound HCP site. Study 4 of the Prescribing Information has the same design and enrollment (783 enrolled, 670 randomized) as SURMOUNT-4.
Zepbound vs Wegovy: which causes more weight loss (SURMOUNT-5)? Note: SURMOUNT-5 results are from the clinical data page of the Zepbound HCP site, which cites Aronne et al., N Engl J Med 2025; the Zepbound Prescribing Information does not describe this trial.
Is Zepbound weight loss maintained at 5 mg or after stopping (SURMOUNT-MAINTAIN)? “Studied in a randomized, phase 3b trial of adults with obesity (BMI ≥30 kg/m2 ), or overweight (BMI ≥27 kg/m2 ) with at least 1 weight-related comorbidity (hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease), excluding diabetes. This study included a 2-week screening period, followed by a 60-week, open-label weight-loss period with participants receiving Zepbound MTD (10 mg or 15 mg), before being randomized 3:3:2 to continue receiving Zepbound MTD (10 mg or 15 mg), reduce the dose to Zepbound 5 mg, or switch to placebo from week 60 to week 112. The overall mean baseline weight was 250.9 lb.18,19 ” (opens the source at this quote in a new tab) Copy Flag
Note: SURMOUNT-MAINTAIN results are from the clinical data page of the Zepbound HCP site, which cites Horn et al., Lancet 2026; the Zepbound Prescribing Information does not describe this trial.
How much weight loss do people keep off on Zepbound (SURMOUNT-MAINTAIN)? Note: The maintenance percentages are among participants who reached a body weight plateau during the 60-week open-label weight-loss period. SURMOUNT-MAINTAIN is not described in the Zepbound Prescribing Information.
How much weight do adults 65 and older lose on Zepbound? Applies to Adults aged 65 and older with obesity, or with overweight and at least one weight-related comorbid condition
Does Zepbound lower blood pressure, cholesterol, and triglycerides? “Table 3: Changes in Anthropometry and Cardiometabolic Parameters at Week 72 in Studies 1 and 2 in Patients with Obesity or Overweight
Abbreviations: ANCOVA = analysis of covariance; CI = confidence interval; N = number of patients randomly assigned to study drug.
a The intention-to-treat population includes all randomly assigned patients. The missing values were imputed by a hybrid approach using retrieved dropouts from the same treatment group (if missing not due to COVID-19) or using all non-missing data assuming missing at random (for missing solely due to COVID-19).
b Least-squares mean from ANCOVA adjusted for baseline value and other stratification factors.
c Analyzed using log-transformed data.
d p-value<0.001 (unadjusted 2-sided) for superiority, controlled for type I error rate.
e Not controlled for type I error rate.
f Least-squares mean from mixed model for repeated measures adjusted for baseline value and other stratification factors.
g Baseline value is the geometric mean.
Study 1 Study 2
Intention-to-Treat (ITT) Populationa
Placebo
N = 643 ZEPBOUND
5 mg
N = 630 ZEPBOUND
10 mg
N = 636 ZEPBOUND
15 mg
N = 630
Placebo
N = 315 ZEPBOUND
10 mg
N = 312 ZEPBOUND
15 mg
N = 311
Waist Circumference (cm)
Baseline mean 114.0 113.2 114.8 114.4 116.0 114.2 114.6
Change from baselineb -4.0 -14.0 -17.7 -18.5 -3.3 -10.8 -13.1
Difference from
placebob (95% CI) -10.1
(-11.6, -8.6)e -13.8
(-15.2, -12.3)d -14.5
(-15.9, -13.0)d -7.4
(-9.0, -5.9)d -9.8
(-11.2, -8.3)d
Systolic Blood Pressure (mmHg)
Baseline mean 122.9 123.6 123.8 123.0 131.0 130.6 130.0
Change from baselineb -1.0 -6.6 -7.7 -7.4 -1.2 -5.6 -7.1
Difference from
placebob (95% CI) -5.6
(-7.2, -3.9)e -6.7
(-8.4, -5.0)e -6.4
(-8.0, -4.8)e -4.4
(-6.7, -2.1)e -5.9
(-8.3, -3.6)e
Diastolic Blood Pressure (mmHg)
Baseline mean 79.6 79.3 79.9 79.3 79.4 80.2 79.7
Change from baselineb -0.8 -4.9 -5.0 -4.5 -0.3 -2.1 -2.9
Difference from
placebob (95% CI) -4.1
(-5.2, -3.0)e -4.2
(-5.3, -3.0)e -3.7
(-4.8, -2.7)e -1.8
(-3.3, -0.4)e -2.7
(-4.2, -1.2)e
Pulse Rate (beats per minute)
Baseline mean 72.9 72.4 71.8 72.4 74.8 75.9 75.6
Change from baselinef 0.1 0.6 2.3 2.6 -0.5 0.6 1.0
Difference from
placebof (95% CI) 0.5
(-0.5, 1.5)e 2.2
(1.2, 3.2)e 2.5
(1.5, 3.4)e 1.2
(-0.1, 2.5)e 1.5
(0.2, 2.8)e
Total Cholesterol (mg/dL)
Baseline meang 187.5 187.1 190.6 187.5 174.9 173.9 167.0
% change from
baselineb -1.8 -3.8 -4.4 -6.3 2.8 -2.8 -1.0
Relative difference
from placebob (95% CI) -2.1
(-4.5, 0.4)c,e -2.7
(-5.1, -0.2)c,e -4.6
(-6.8, -2.2)c,e -5.5
(-8.7, -2.2)c,e -3.8
(-7.1, -0.3)c,e
LDL Cholesterol (mg/dL)
Baseline meang 109.4 108.7 112.3 109.3 92.4 90.5 85.7
% change from
baselineb -1.7 -4.6 -5.6 -7.1 7.4 1.8 4.1
Relative difference
from placebob (95% CI) -2.9
(-6.6, 0.9)c,e -4.0
(-7.5, -0.5)c,e -5.5
(-8.9, -2.0)c,e -5.2
(-10.1, 0.1)c,e -3.0
(-8.4, 2.6)c,e
HDL Cholesterol (mg/dL)
Baseline meang 46.6 47.6 47.6 47.6 42.7 43.8 42.2
% change from
baselineb -0.7 6.9 9.2 8.0 0.2 8.2 9.7
Relative difference
from placebob (95% CI) 7.7
(4.6, 10.8)c,e 9.9
(6.7, 13.2)c,e 8.7
(5.7, 11.8)c,e 8.0
(4.2, 11.8)c,e 9.5
(5.6, 13.5)c,e
Non-HDL Cholesterol (mg/dL)
Baseline meang 138.3 137.0 140.4 137.5 129.6 127.2 121.9
% change from
baselineb -2.3 -8.0 -9.4 -11.7 3.7 -6.6 -5.2
Relative difference
from placebob (95% CI) -5.8
(-8.9, -2.6)c,e -7.2
(-10.3, -4.1)c,e -9.6
(-12.4, -6.6)c,e -9.9
(-14.1, -5.6)c,e -8.5
(-12.9, -4.0)c,e
Triglycerides (mg/dL)
Baseline meang 130.8 128.7 125.7 128.1 165.0 158.8 158.5
% change from
baselineb -5.6 -21.2 -23.8 -29.1 -3.3 -27.1 -27.3
Relative difference
from placebob (95% CI) -16.5
(-21.2, -11.4)c,e -19.3
(-23.9, -14.4)c,e -24.9
(-29.1, -20.4)c,e -24.6
(-30.0, -18.7)c,e -24.8
(-30.3, -18.9)c,e” (opens the source at this quote in a new tab) Copy Flag
Note: Table 3 columns are, for Study 1, placebo, ZEPBOUND 5 mg, 10 mg, and 15 mg, then, for Study 2, placebo, ZEPBOUND 10 mg, and 15 mg; footnote e marks results not controlled for type I error. The clinical data page of the Zepbound HCP site reports HDL cholesterol, systolic blood pressure, and triglycerides for pooled Zepbound doses in SURMOUNT-1 as controlled for type I error.